Sutura, Inc.

Sutura, Inc.
Technology Visions Group, Inc.
OTC Bulletin Board : TVGR

July 05, 2005 08:37 ET

Sutura Issued Chinese Patent for Vascular Suturing Technology; Sutura Expands Intellectual Property Portfolio in China

FOUNTAIN VALLEY, CALIFORNIA--(CCNMatthews - July 5, 2005) - Sutura®, Inc. ("Sutura"), a California-based medical device company, announced today that the State Intellectual Property Office of the Peoples Republic of China has issued Sutura a patent for its vascular suturing technology. The Chinese patent is the 8th such patent Sutura has received for the Company's main SuperStitch® technology.

"We believe securing the Chinese patent is a critical step as we move to protect our intellectual property worldwide and introduce our product in Southeast Asia," said Anthony Nobles, CEO/President of Sutura. "In the medical device community, it is imperative that we protect our technology and it is one of the keys to our strategic market position. In addition, as we expand the marketing of Sutura's new 'As Simple As 1-2-3 Concept' we will continually add to our intellectual property portfolio and seek additional patents worldwide to protect our SuperStitch asset."

Sutura, Inc. announced November 22, 2004 that it had signed an Agreement and Plan of Merger with Technology Visions Group, Inc. (OTCBB:TVGR) of San Marcos, California. The merger is now proceeding through due diligence and satisfaction of closing conditions.

About Sutura, Inc.

Sutura, Inc. (www.suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive vascular suturing devices to suture the arteriotomy created in an artery during open surgery and catheter-based procedures,. The SuperStitch devices allow physicians to suture the arteriotomy site directly or using the catheter sheath introducer to access the artery. Sutura has received 510(k) clearance from the FDA to sell its F8 & F6 SuperStitch devices in the United States in open surgical procedures or under fluoroscopically guided procedures and has the CE mark permitting sale in Europe. Sutura has also met all of the registration requirements for selling the SuperStitch devices in Australia. Sutura's headquarters are in Fountain Valley, California. "Sutura" and "SuperStitch" are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch® devices by medical providers and the marketplace in general and the success of the proposed marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.

Contact Information

  • Sutura, Inc.
    Barry Forward
    Corporate Communications
    1-866-676-8386
    www.suturaus.com